Hyperhomocysteinemia in end stage renal disease: is treatment necessary?
Hyperhomocysteinemia occurs in 85% of patients with end stage renal disease (ESRD) and may contribute to their increased risk of cardiovascular disease (CVD). This population experiences excess morbidity and mortality due to CVD, presenting a unique challenge in terms of preventative medicine. The treatment of hyperhomocysteinemia in the renal population has been a topic recently considered in published studies. It is thought, but not yet supported by evidence, that lowering homocysteine (Hcy) levels in ESRD patients will decrease the incidence of CVD. Nephrology nurses need to be aware of the pathophysiology, treatment, and current research regarding hyperhomocysteinemia in patients with ESRD and integrate this knowledge into clinical practice.
Snavely
Jennifer
J
D001161:Arteriosclerosis / Q000209:etiology; D005492:Folic Acid / Q000627:therapeutic use; D006801:Humans; D020138:Hyperhomocysteinemia / Q000150:complications* / Q000451:nursing; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications*
D005492:Folic Acid